Efruxifermin Improves Fibrosis in Long-Term MASH Study
In this double-blind, placebo-controlled trial, 181 participants were randomised to receive weekly injections of either 28 mg or 50 mg of efruxifermin or a placebo.
Allergy & Immunology
